Interferon Alfa 2a
Links shared publicly online about this topic
Oncology Medical News about Carcinoma, Renal Cell Interferon Alfa-2a
mdlinx.com — “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma : An open-label randomised trial” View full resource at mdlinx.com
Most Recently Shared on February 22, 2010 at 9:43 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Oncology Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in... http://bit.ly/bj93W1
Oncology Medical News about Carcinoma, Renal Cell Interferon Alfa-2a
mdlinx.com — “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An open-label randomised trial” View full resource at mdlinx.com
Most Recently Shared on February 12, 2010 at 9:33 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Oncology Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in... http://bit.ly/clZRAX
Oncology Medical News about Carcinoma, Renal Cell Interferon Alfa-2a Survival
mdlinx.com — “Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival” View full resource at mdlinx.com
Most Recently Shared on April 9, 2010 at 9:11 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (... http://bit.ly/aDh6t1 #oncology
Interferon alfa-2a versus combination therapy with... [Lancet. 2010] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 12, 2010 at 9:08 am By:
ACOR Kidney Cancer Health Organization
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in... - http://bit.ly/b8ilOB
interferon alfa effective in behcet's
eyedocnews.com — “dose-escalating interferon controlled behcet's in 95% of patients” View full resource at eyedocnews.com
Most Recently Shared on April 12, 2011 at 9:32 am By:
Dr. Ari Weitzner Doctor, Ophthalmologist, and Physician
Discuss: Interferon Controls Behcet’s Disease: Archives: Behcet’s disease is an uncommon inflammatory disease wh... http://bit.ly/fXk5i4
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial Of PSI-7977 For Chronic Hepatitis C
medicalnewstoday.com — “Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The t” View full resource at medicalnewstoday.com
Most Recently Shared on December 15, 2010 at 6:05 pm By:
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial Of PSI-7977 For Chronic Hepatitis C http://mnt.to/3P6G #liver #hepatitis
Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma | HemOncToday
hemonctoday.com — “Prolonging conventional low-dose interferon alpha2a therapy from 18 months to 60 months for patients with intermediate or high-risk lymph-node” View full resource at hemonctoday.com
Most Recently Shared on January 15, 2010 at 1:15 pm By:
HemOnc Today Oncology and Health News
#JCO Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma http://ow.ly/WMyT
HCV New Drug Research: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
hepatitiscnewdrugs.blogspot.com — “HCV New Drug Research: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus” View full resource at hepatitiscnewdrugs.blogspot.com
Most Recently Shared on April 22, 2011 at 12:27 pm By:
Tina Banwart - HepatitisCNewDrugs Health Blog
A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic… http://goo.gl/fb/rCeLE
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients With Chronic HCV Genotype 1
medicalnewstoday.com — “MSD reported that final results from a Phase III study of 'Victrelis'™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a ('Pegasys'®)” View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2011 at 11:05 pm By:
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients ... http://mnt.to/3T54
HCV New Drug Research: Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and qua
hepatitiscnewdrugs.blogspot.com — “HCV New Drug Research: Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and qua” View full resource at hepatitiscnewdrugs.blogspot.com
Most Recently Shared on February 9, 2011 at 10:29 pm By:
Tina Banwart - HepatitisCNewDrugs Health Blog
Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in… http://goo.gl/fb/MkblQ
HCV New Drug Research: Hepatitis C/Aplastic Anemia Asso/w Interferon Alpha 2a/Case Report
hepatitiscnewdrugs.blogspot.com — “HCV New Drug Research: Hepatitis C/Aplastic Anemia Asso/w Interferon Alpha 2a/Case Report” View full resource at hepatitiscnewdrugs.blogspot.com
Most Recently Shared on November 7, 2010 at 2:09 am By:
Tina Banwart - HepatitisCNewDrugs Health Blog
Hepatitis C/Aplastic Anemia Asso/w Interferon Alpha 2a/Case Report http://goo.gl/fb/zMcJ4
Journal of Medical Case Reports | Full text | Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report
jmedicalcasereports.com — “Journal of Medical Case Reports | Full text | Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report” View full resource at jmedicalcasereports.com
Most Recently Shared on August 13, 2010 at 8:54 am By:
JMedCaseReports Medical Journal
Latest JMCR:"Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection" http://bit.ly/9p077i
Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer | HemOncToday
hemonctoday.com — “Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 23, 2010 at 6:25 pm By:
HemOnc Today Oncology and Health News
Adjuvant chemoradiation plus interferon alfa-2b did not improve survival in pancreatic cancer http://ht.ly/22dEz
EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma | HemOncToday
hemonctoday.com — “EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 5, 2010 at 10:15 pm By:
HemOnc Today Oncology and Health News
EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma http://ht.ly/1UzGp #ASCO10
Interferon-alfa sustained remission following imatinib discontinuation in CML | HemOncToday
hemonctoday.com — “Patients with chronic myeloid leukemia frequently relapse after discontinuation of imatinib, but results of a recently published study indica” View full resource at hemonctoday.com
Most Recently Shared on February 16, 2010 at 3:44 pm By:
HemOnc Today Oncology and Health News
Interferon-alfa sustained remission following imatinib discontinuation in CML http://ow.ly/17S2j
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
